Targeting CD30 in Hodgkin Lymphoma

Video

For High-Definition, Click

According to John Sweetenham, MD, it has been well known for a number of years that there is cell communication within the Hodgkin lymphoma lymph node that is important to cell survival, particularly between Reed-Sternberg cells and inflammatory background infiltrate. Now, new data suggest that Reed-Sternberg cells form a network of cells that are linked by CD30-bearing protrusions. Cross talk mechnisms may exist between the Reed-Sternberg cells and the protrusions that express CD30, making CD30 an even better target for therapy, Sweetenham suggests.

Until the approval of the antibody-drug conjugate brentuximab vedotin, CD30 remained an elusive target. Brentuximab vedotin binds to CD30 and internalizes, causing the release of the anti-tubulin cytotoxic MMAE within the cancer cell. MMAE works to disrupts the microtubule network, causing cell cycle arrest and apoptosis. Targeting tubulin helps break down the protrusions and membrane-bound vesicles, resulting in a loss of cell communication and reduced survival of Reed-Sternberg cells.

Related Videos
Lori A. Leslie, MD
Changchun Deng, MD, PhD
Guenther Koehne, MD, PhD
Ibrahim Aldoss, MD
Andrew P. Jallouk, BS, MD, PhD, assistant professor, Vanderbilt University
Elias Jabbour, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Ibrahim Aldoss, MD
Kateryna Fedorov, MD, assistant professor, hematology-oncology, Vanderbilt University Medical Center
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Annie Im, MD, FASCO